Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) from HDL to apolipoprotein (apo) B-containing lipoproteins and plays a crucial role in reverse cholesterol transport, which is a major protective system against atherosclerosis. Genetic CETP deficiency is the most common cause of a marked hyperalphalipoproteinemia (HALP) in the Japanese, and various mutations have been identified in the coding region as well as in the exon/intron boundaries in the CETP gene. In the present study, we identified a novel mutation in the promoter region of the CETP gene. This mutation was a G-to-A substitution at the Ϫ69 nucleotide of the promoter region (Ϫ69 G3 A), corresponding to the second nucleotide of the PEA3/ETS binding site (CGGAA) located upstream of the putative TATA box. Four (2.0%) of 196 unrelated subjects with a marked HALP (HDL cholesterol Ն2.59 mmol/Lϭ100 mg/dL) were revealed to be heterozygous for the Ϫ69 G3 A mutation, and the allelic frequency of the mutant was 0.0102 in the subjects with a marked HALP. The subjects with the Ϫ69 G3 A mutation had low plasma CETP levels. Reporter gene assay showed that this mutation markedly reduced the transcriptional activities in HepG2 cells (8% of wild type). These results suggested that this mutation would be dominant negative. In conclusion, a novel Ϫ69 G3 A mutation in the CETP gene causes the decreased transcriptional activity leading to HALP. (Arterioscler Thromb Vasc Biol. 2001;21: 985-990.) Key Words: cholesteryl ester transfer protein deficiency Ⅲ hyperalphalipoproteinemia Ⅲ mutation Ⅲ
C holesteryl ester transfer protein (CETP) is a plasma glycoprotein that catalyzes the transfer of cholesteryl ester (CE) from HDL to apolipoprotein (apo) B-containing lipoproteins and is one of the major determinants of plasma HDL cholesterol levels. [1] [2] [3] Genetic CETP deficiency is the most common cause of hyperalphalipoproteinemia (HALP) in the Japanese. 4 -10 It has been demonstrated that a G-to-A substitution at the 5Ј splice donor site of intron 14 (Int14 ϩ1 G3 A) and a missense mutation of exon 15 (D442G) in the CETP gene are common mutations associated with HALP. These 2 mutations are relatively frequent in the Japanese population. 5, 7, 8, 10 Patients with CETP deficiency have moderate hypercholesterolemia and markedly increased levels of HDL cholesterol. The lipoprotein abnormalities in CETP deficiency are also characterized by the presence of polydisperse LDL enriched with triglycerides and large, CE-rich HDL particles. [11] [12] [13] [14] These results indicated that CETP is involved in the regulation of plasma lipoproteins by modulating both the quantity and quality of each lipoprotein particle.
In addition, CETP plays an important role in reverse cholesterol transport from peripheral tissues to the liver. 15, 16 Recently, CETP deficiency has been thought to be a proatherogenic state because of the crucial role of CETP in reverse cholesterol transport despite high HDL cholesterol levels. The study of the Omagari area in Japan, where the Int14 ϩ1 G3 A mutation is extremely frequent, indicated that a marked HALP caused by CETP gene mutation may not represent a longevity syndrome. 17 The Honolulu Heart Program demonstrated that the prevalence of coronary heart disease in men with CETP gene mutation was increased. 18 Therefore, genetic CETP deficiency appears to be an independent risk factor for coronary heart disease. In the present study, we screened CETP gene mutations in 196 marked HALP subjects and identified a novel one in the promoter region of the CETP gene. Furthermore, we investigated the effects of this novel mutation on lipoprotein metabolism and its prevalence in the Japanese HALP subjects. mg/dL) were referred to the lipid clinic in Osaka University Hospital and Nakajima Clinic in Omagari City, Akita Prefecture. Among these subjects, 196 had a marked HALP (HDL cholesterol Ն2.59 mmol/Lϭ100 mg/dL). Subjects with primary biliary cirrhosis, nephrotic syndrome, and thyroid dysfunction and massive alcohol drinkers (Ն80 g/d) were excluded from this study. Ninety healthy normolipidemic subjects (53 men and 37 women) were examined as control subjects.
Lipoprotein Preparation
LDL (1.006ϽdϽ1.063 g/mL) was isolated from human plasma by sequential ultracentrifugation in a Beckman Ti 50.2 rotor with solid KBr to adjust the density at 1.063 g/dL. 19 LDL was extensively dialyzed against PBS (pH 7.4) containing 1 mmol/L EDTA and 0.02% NaN 3 and stored at 4°C.
Measurement of CETP Activity
The plasma CETP activity was determined according to the method described by Kato et al, 20 with minor modifications. In brief, 80 L of diluted (1:40) plasma sample was added to 70 L of reaction mixture containing LDL (65 g protein) and reconstituted HDL consisting of 36 g apoA-I and 0.94 nmol [1-14 C]cholesteryl oleate and incubated at 37°C for 30 minutes. LDL was then precipitated with 30 L of 0.05% dextran sulfate and 30 mmol/L MgCl 2 , and the radioactivity in the precipitates was measured by a scintillation counter (Beckman LS5000TD). CETP activity was expressed as the percentage of pooled normal plasma compared with control levels, in which CETP activity was 360Ϯ69 nmol · h Ϫ1 · mL Ϫ1 . The intra-assay and interassay (nϭ8) coefficients of variation were 2.7% and 6.0%, respectively.
Measurement of CETP Mass
The plasma CETP mass was measured by a sandwich ELISA using 2 monoclonal antibodies (mAbs) specific to human CETP, JHC1 and JHC2, as described. 21 In brief, 100 L of mAb JHC1 (20 g/mL) in PBS was coated on a plate (Nunc Immunoplate II MaxiSorp) by incubation at 4°C overnight. The wells were then blocked with 200 L of PBS containing 1% BSA (Sigma Chemical Co) for 2 hours at room temperature. After the plate had been washed with PBS containing 0.1% Tween 20, 100 L of standard solution or diluted 1:400 plasma samples was added and incubated for 2 hours at room temperature. After washing, 100 L of biotinylated mAb JHC2 (0.1 g/mL) was added to each well and incubated for 1 hour at room temperature. After washing, 100 L of horseradish peroxidaseconjugated streptavidin (1 g/mL) (Vector Laboratories, Inc) was added and incubated for 30 minutes, followed by incubation with 100 L of substrate solution containing 0.25 mg/mL o-phenylenediamine and 0.6% H 2 O 2 . After 30 minutes, the reaction was stopped by the addition of 100 L of 2N H 2 SO 4 . Absorbance at 492 nm was measured by a plate reader (Labsystems). A pooled culture medium from Raji cells expressing recombinant human CETP was used as a secondary standard and purified human CETP as a primary standard. The assay range of the ELISA method was from 0.025 to 1.5 ng CETP/well. The assay was performed in duplicate for each sample. The intra-assay and interassay (nϭ8) coefficients of variation were 2.7% and 7.8%, respectively. No interfering effect on ELISA assay was observed with hemoglobin (10 g/L), bilirubin (0.2 g/L), or triacylglycerol (4.25 g/L). There was a strong positive correlation between plasma CETP mass and CETP activity (rϭ0.940, PϽ0.001).
Polymerase Chain Reaction
Genomic DNA was isolated from whole blood with a QIAamp Blood Kit (Qiagen). The promoter region and each exon of the CETP gene were individually amplified by polymerase chain reaction (PCR). In general, PCR was carried out on Ϸ0.1 g of genomic DNA in a buffer containing 10 mmol/L Tris (pH 8.3), 50 mmol/L KCl, 0.2 mmol/L each dNTP, 1.5 mmol/L MgCl 2 , 0.2 nmol/L of each primer, and 0.5 U Taq polymerase (Perkin-Elmer Cetus). PCR conditions were denaturation at 95°C for 5 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 56°C to 65°C for 30 seconds, and extension at 70°C for 1 minute, with final extension at 72°C for 10 minutes. The abundance and quality of DNA fragments were analyzed by electrophoresis on 3% agarose gels, followed by ethidium bromide staining and inspection under UV light.
Mutation Screening Using PCR-Restriction Fragment Length Polymorphism Analysis
The 6 known mutations were analyzed by PCR-restriction fragment length polymorphism (RFLP). The PCR amplification was performed with pairs of primers: 5Ј-CAGGGGCTCATTGTGGTGCT-3Ј (sense), 5Ј-GACCACAGGGAGTCAGCCAG-3Ј (antisense) for G181X 22 ; 5Ј-GGACTTTACTCCACCCACC-3Ј (sense), 5Ј-GGATTGGGGTA-CGTGAGTAAAC-3Ј (antisense) for Q309X 23 and Int10 ϩ2 T3 G 24 ; 5Ј-CTTCTGTGCTCCAGGGAGGACTCA-3Ј (sense), 5Ј-CAGTTTC-CCCTCCAGCCCACACAT-3Ј (mismatch primer, antisense) for Int14 ϩ1 G3 A 4 -6 and Int14 ϩ3 T ins 7 ; and 5Ј-CAGCAAAGGCGTGA-GCCTGGTC-3Ј (mismatch primer, sense), 5Ј-CCCAGGAATCCT-GTCTGGGCC-3Ј (antisense) for D442G. 9, 10 The amplified PCR products were digested with the restriction enzymes MaeIII for G181X, DdeI for Q309X, MaeIII for Int10 ϩ2 T3 G, NdeI for Int14 ϩ1 G3 A, HpaI for Int14 ϩ3 T ins, and SalI for D442G at 37°C for 3 hours. After digestion, the reaction mixture was electrophoresed on a 10% polyacrylamide gel. After staining with ethidium bromide, DNA fragments were visualized on a standard UV transilluminator. The novel Ϫ69 G3 A mutation was also analyzed by PCR-RFLP. A substitution of G to A at nucleotide Ϫ69 in the promoter region of the CETP gene caused the disappearance of a restriction site for HapII. A 371-bp fragment was amplified with a pair of primers: 5Ј-AAAATGGTGCAGATG-GTGGAGGG-3Ј (sense) and 5Ј-GATGCTACTGATACTTA-CACAACCAG-3Ј (antisense). By digestion with HapII, PCR products yielded a fragment of 371 bp in the wild allele and fragments of 232 bp and 139 bp in the mutated allele.
Direct Sequencing of PCR Products
PCR products were purified with the QIAquick Gel Extraction Kit (Qiagen). Gel-purified products were sequenced by an ABI Prism 377 DNA sequencer (Applied Biosystems) using a BigDye Terminator Cycle Sequencing Kit (Perkin-Elmer Cetus).
Construction of the Promoter-Luciferase Fusion Plasmid
For evaluating the transcriptional activity in the promoter region of the CETP gene, we constructed a plasmid consisting of 164-bp and 570-bp promoter sequences of the CETP gene. Each promoter region was obtained by PCR using the primers 5Ј-CAGCACTTGGTCATCTG-GTCAC-3Ј (sense) and 5Ј-GTAAGTGGCTCGAGCCGTTCA-GCCTGGA-3Ј (antisense) for the 164-bp fragment and 5Ј-AGTTGGGGTACCCTTGTTGAATGTCTGGCTCTGAACTC-3Ј (sense) for the 570-bp fragment. The PCR products were digested with KpnI and XhoI and then ligated to PicaGene basic vector 2 (Wako Pure Chemicals Industries Ltd), constructing plasmids pCETP Ϫ570 (Ϫ69 G) luc or pCETP Ϫ570 (Ϫ69 A) luc and pCETP Ϫ164 (Ϫ69 G) luc or pCETP Ϫ164 (Ϫ69 A) luc, respectively.
Cell Culture and Transient Transfection Analysis
HepG2 cells were obtained from the American Type Culture Collection. Cells were cultured in Dulbecco's MEM (Gibco BRL) supplemented with 10% FCS (JRH Bioscience), 100 U/mL penicillin, and 100 g/mL streptomycin in 5% CO 2 at 37°C. One day before the transfection procedure, HepG2 cells (2ϫ10 5 cells/well) were plated onto 6-well plates (Iwaki Glass). After 24 hours of incubation, 1.0 g of each plasmid was transfected into the cells by use of the Fugene 6 Transfect Reagent (Boehringer Mannheim) along with 0.5 g of the pSV-␤gal plasmid (Promega) to calibrate the transfection efficiency. The cells were harvested 24 hours after transfection with 250 L of lysis buffer LCB (Wako Pure Chemicals Industries Ltd). Luciferase and ␤-galactosidase activities in the lysate were then determined with a Picagene Luminescence Kit (Wako Pure Chemicals Industries Ltd) and an Aurora GAL-XE kit (ICN), respectively, according to the manufacturer's instruction. The luciferase activity was normalized with the ␤-galactosidase activity for the transcriptional activities of the vector. The transfection experiment was carried out in triplicate and repeated 3 times for each experiment. Luciferase activity for the control vector was 0.37ϫ10 6 relative luciferase units (RLU).
Analytical Methods
Total cholesterol, triglyceride, and HDL cholesterol in plasma were measured with an automated analyzer (Hitachi 7450) and commercial kits (Daiichi Pure Chemical Industries Co Ltd). LDL cholesterol concentration was calculated according to the equation of Friedewald et al. 25 Plasma concentrations of apos A-I, A-II, B, C-II, C-III, and E were measured by the immunoturbidimetry method (Daiichi Pure Chemical Co Ltd).
Results
In the present study, we analyzed plasma CETP mass and activity in 196 unrelated Japanese subjects with a marked HALP (HDL cholesterol Ն2.59 mmol/Lϭ100 mg/dL), in which plasma levels of total cholesterol, HDL cholesterol, and triglyceride averaged 6.31Ϯ1.16 (meanϮSD), 3.21Ϯ0.65, and 0.88Ϯ0.49 mmol/L, respectively (Table 1) . Plasma CETP mass and activity in 196 marked HALP subjects were 1.6Ϯ1.1 g/mL and 68Ϯ43%, respectively. Subsequently, the 6 known mutations in the CETP gene, G181X, Q309X, Int10 ϩ2 T3 G, Int14 ϩ1 G3 A, Int14 ϩ3 T ins, and D442G, were screened by PCR-RFLP analysis. We detected 1 homozygote with G181X, 31 with Int14 ϩ1 G3 A, and 6 with D442G. There were also 1 heterozygote with G181X, 27 with Int14 ϩ1 G3 A, and 32 with D442G. Two compound heterozygotes with Int14 ϩ1 G3 A and G181X, and with Int14 ϩ1 G3 A and Int14 ϩ3 T ins, and 15 with Int14 ϩ1 G3 A and D442G were also identified. No subjects with Q309X and Int10 ϩ2 T3 G were identified in this study. Among 196 marked HALP subjects, 118 subjects (60%) had Ն1 of these known mutations (Figure 1 ).
In 8 of 78 marked HALP subjects without known mutations, plasma CETP levels were Ͻ60% of controls (CETP mass Ͻ1.4 g/mL), suggesting the presence of other unknown mutation(s) in the CETP gene (Figure 1 ). Subsequently, 17 exons and the promoter region of the CETP gene were analyzed by direct sequencing. Thus, a novel mutation has been identified in the promoter region of the CETP gene in a subject with low plasma CETP mass (0.9 g/mL) and activity (43% of control levels). This mutation was a G-to-A nucleotide substitution at the Ϫ69 nucleotide in the promoter region (Ϫ69 G3 A) (the number indicates the location from the transcription start point, ϩ1) ( Figure 2 ). The nucleotide substitution was revealed at the second nucleotide of the ETS binding site (CGGAA), which has been described as the PEA3 motif, 26 located upstream of the putative TATA box. The proband was a 22-year-old woman, and her plasma total cholesterol and triglyceride levels were 5.53 and 0.66 mmol/L, respectively. Her HDL cholesterol concentration was moderately elevated (2.92 mmol/L).
Furthermore, we screened the Ϫ69 G3 A mutation with PCR-RFLP analysis in 466 unrelated HALP (HDL cholesterol Ն2.07 mmol/Lϭ80 mg/dL) subjects, including 196 marked HALP subjects, and found 6 subjects with this mutation (Table 1 ). Of 6 HALP subjects with this mutation, 1 was a compound heterozygote with Ϫ69 G3 A and G181X and 2 with Ϫ69 G3 A and D442G. The allelic frequencies of the Ϫ69 G3 A mutation were calculated to be 0.0102 and 0.0037 in the marked HALP and HALP subjects, respectively ( Table 1) . The CETP mass level in 5 subjects with the novel mutation ranged from 0.4 to 1.6 g/mL, suggesting that their plasma CETP levels were similar to those with the heterozygous Int14 ϩ1 G3 A mutation (Table 2 ). Furthermore, a compound heterozygote with Ϫ69 G3 A and G181X had markedly elevated plasma HDL cholesterol (3.65 mmol/L) and significantly decreased CETP activity (13%), a lipid profile similar to that observed in subjects with a homozygous Int14 ϩ1 G3 A mutation ( Table 2) . To know the mechanism by which the mutation causes a reduction of CETP mass and activities, we performed transfection experiments for the transcriptional activity at the PEA3/ETS binding site of the CETP gene. The major site of CETP mRNA expression is liver. 27 It has been shown that isolated human hepatocytes express CETP mRNA and that the human hepatocyte-derived cell line HepG2 secretes CETP. 28, 29 Therefore, we performed transfection experiments for transcriptional activity using HepG2 cells. The 164-bp and 570-bp promoter regions of the CETP gene were cloned into luciferase reporter gene vector and transfected into HepG2 cells to measure transcriptional activities (Figure 3) . The luciferase activity in the mutant, pCETP Ϫ164 (Ϫ69 A) luc or pCETP Ϫ570 (Ϫ69 A) luc, was markedly decreased compared with that in the wild-type sequence, pCETP Ϫ164 (Ϫ69 G) luc or pCETP Ϫ570 (Ϫ69 G) luc (11.32ϫ10 6 versus 1.22ϫ10 6 RLU, and 4.33ϫ10 6 versus 0.38ϫ10 6 RLU, respectively), indicating a markedly reduced transcriptional activity in the mutation of the PEA3/ETS binding site.
Discussion
In the present study, we have identified a novel G-to-A mutation in subjects with a marked HALP, which was located in the promoter region of the CETP gene. This is the first mutation identified in the promoter region of the CETP gene. The novel mutation is a G-to-A substitution at the Ϫ69 nucleotide in the promoter region (Ϫ69 G3 A), which is located in the consensus ETS binding site designated as the PEA3 motif. 26 The allelic frequency of the Ϫ69 G3 A mutation was lower than the other common mutations in the CETP gene; however, this mutation was identified in 6 unrelated subjects with HALP, whose lipid profiles and plasma CETP levels were similar to those with the known CETP deficiency. Furthermore, the luciferase promoter assay clearly demonstrated that the mutated promoter almost lost its activity in HepG2 cells. These results strongly suggested that the mutation in the PEA3/ETS binding site of the CETP gene would cause the reduction of CETP mass, leading to HALP.
To date, 22 ETS transcriptional factors have been identified in mammalians, which bind to the ETS binding site. 30 All of these ETS transcriptional factors have DNA binding regions, so-called ETS domains. These transcriptional factors were classified into 9 groups based on the similarity of the ETS domain, ie, PEA3, ETS, ERG, ERF, ELG, ELK, ELF, YAN, and SPI. The ETS domain contains the structure of branched helix-loop-helix and binds to the ETS binding site: consensus sequence, 5Ј-(C/A)GGA(A/T)-3Ј. Although the PEA3/ETS binding site is believed to be quite important for promoter activity, spontaneous mutations at some PEA3/ETS binding site(s) appeared to be very rare. To our best knowledge, there was only 1 example that the PEA3/ETS binding site was mutated in the human disorder, reported by Nichols et al. 31 They found a G-to-A mutation at the second nucleotide of the PEA3/ETS binding site located at the promoter region of the acetylcholine receptor E subunit gene in a white patient with congenital myasthenic syndrome. In the CETP gene, 2 putative PEA3/ETS binding sites have been identified within 100-bp promoter regions. 26, 32 The mutation found was located just upstream of the putative TATA box. The importance of the particular PEA3/ETS binding site may be supported by the site-directed mutagenesis study performed by Gaudet and Ginsburg. 33 They extensively mutated the same PEA3/ETS binding site and examined transcriptional activity, showing that the mutated PEA3/ETS binding site (CGGAA3 CGTAT) reduced the transcriptional activity to 40% of the wild type and lacked the specific binding of nuclear extracts in both HepG2 cells and Caco-2 cells. In the promoter region of the CETP gene, there are also several binding sites for transcriptional factors, such as the LXR element, retinoic acid receptor element, orphan nuclear hormone receptor response element, and Sp1 site. 26, [32] [33] [34] It would be interesting to know the functional interaction between the PEA3/ETS transcriptional factor(s) and other transcriptional factors in the promoter region of the CETP gene.
Although HALP was thought to be heterogeneous, the present study confirmed the previous reports that CETP deficiency contributed to 60% of HALP in Japan. 24 We have shown that a marked HALP caused by CETP gene mutation is the impairment of reverse cholesterol transport. In addition, knockout mice of scavenger receptor class B type I with high levels of plasma HDL cholesterol caused accelerated atherosclerosis in the apoE-negative background. 35 These data indicated that HALP is not always beneficial, but rather may be atherogenic. Therefore, elucidation of the molecular basis and pathophysiology in HALP other than CETP deficiency is the important issue for the future. Transcriptional activity in HepG2 cells transfected with CETP-promoter/reporter-gene constructs. HepG2 cells were transfected with luciferase-plasmids containing a promoter fragment of wild type and the same fragment containing a mutation at the Ϫ69 nucleotide, denoted as pCETP (Ϫ69 G) luc and pCETP (Ϫ69 A) luc, respectively. A reporter vector with 570 bp or 164 bp of the CETP promoter regions was generated. The luciferase activity was normalized with ␤-galactosidase activity to establish the transcriptional activities of the vector. Values represent meanϮSD of 3 separate experiments. The luciferase activity in the mutant, pCETP (Ϫ69 A) luc, was markedly decreased compared with that in the wild-type sequence, pCETP (Ϫ69 G) luc (*PϽ0.001 by unpaired t test).
